Abstract
Overview
Introduction
This analysis examines the historical and forecast performance for Takeda in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Key reasons to read this report
- Benchmark Takeda' s performance against key rivals in the ethical pharmaceutical sector
- Assess Takeda' s reliance on four key blockbuster drugs: Actos, Prevacid, Blopress and Lupron
- See how this dependency on these four drugs will be exposed over the forecast period, as they all face some form of generic competition to 2012
View Cart
